To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Provider Data DescriptionThis dataset will allow users to reproduce the treatment comparison between arms in trial NCT00331773.
SponsorRadiation Therapy Oncology Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryRATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period of time), may be less costly with fewer side effects and just as effective in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying several different radiation therapy regimens to compare how well they work in treating patients with stage II prostate cancer.
Intervention TypeRadiation: Conventional 3D-CRT or IMRT Radiation: Hypofractionated 3D-CRT or IMRT
Blinding MethodNone (Open Label)
Arms InterventionConventional 3D-CRT - Active Comparator Hypofractionated 3D-CRT - Experimental
PubMed (PMID)27044935 35776901 30763425
Collaborator(s)National Cancer Institute (NCI) NRG Oncology
Region(s)United States Canada
Age Range18 Years to 120 Years (Adult, Older Adult)